Hiyama E, Hiyama K, Yokoyama T, Fukuba I, Yamaoka H, Shay J W, Matsuura Y
Department of General Medicine, Hiroshima University School of Medicine, Hiroshima, Japan.
Clin Cancer Res. 1999 Mar;5(3):601-9.
Amplification of the MYCN gene and high telomerase activity predict a poor prognosis for the patients with neuroblastoma. We used PCR techniques for rapid detection of MYCN gene amplification and human telomerase reverse transcriptase (hTERT) expression in neuroblastoma specimens. The detection of MYCN gene amplification is based on differential PCR in which three primer pairs were used to coamplify a 178-bp fragment of target MYCN gene with two reference gene fragments, a 237-bp of p53 exon 7 and a 120-bp of beta-globin exon 3, in a single tube of 40 surgically resected tumor samples. MYCN amplification was identified by this differential PCR in all 10 samples carrying more than 10 copies (already known to have MYCN gene amplification by Southern blot analysis). There were no false-negative or false-positive cases, and the relative intensity of MYCN bands in the differential PCR correlated significantly with the copy number determined by Southern blot analysis (y = 0.99, P<0.0001). This protocol was also applicable in the biopsy or aspirated samples, as well as the paraffin-embedded tissues, and in detecting intratumoral heterogeneity. Using RT-PCR procedures, hTERT mRNA expression was detectable in all 13 tumors with high telomerase activity. These nonradioisotopic PCR-based protocols for detecting MYCN gene amplification and hTERT mRNA expression are rapid and reliable and are likely to be useful to determine the biological behavior of neuroblastoma.
MYCN基因扩增和高端粒酶活性预示着神经母细胞瘤患者预后不良。我们采用聚合酶链反应(PCR)技术快速检测神经母细胞瘤标本中的MYCN基因扩增和人端粒酶逆转录酶(hTERT)表达。MYCN基因扩增的检测基于差异PCR,在40份手术切除的肿瘤样本的单管反应中,使用三对引物共同扩增目标MYCN基因的178bp片段以及两个参照基因片段,即p53第7外显子的237bp片段和β-珠蛋白第3外显子的120bp片段。通过这种差异PCR在所有10份携带超过10个拷贝的样本中鉴定出MYCN扩增(通过Southern印迹分析已知这些样本有MYCN基因扩增)。没有假阴性或假阳性病例,差异PCR中MYCN条带的相对强度与Southern印迹分析确定的拷贝数显著相关(y = 0.99,P<0.0001)。该方法也适用于活检或穿刺样本以及石蜡包埋组织,还可用于检测肿瘤内异质性。采用逆转录聚合酶链反应(RT-PCR)方法,在所有13例端粒酶活性高的肿瘤中均可检测到hTERT mRNA表达。这些基于非放射性同位素PCR的检测MYCN基因扩增和hTERT mRNA表达的方法快速可靠,可能有助于确定神经母细胞瘤的生物学行为。